Breast cancer claimed the lives of approximately 40,610 women and 460 men in 2017, and the number of cases is projected to rise in the coming years. As a result, the rise in breast cancer prevalence is a major contributor to the global breast implant market’s revenue growth.
Market growth is driven primarily by the growing number of surgeries for breast augmentation and the increasing awareness of cosmetic surgery.
Download Free PDF Sample Copy at
https://www.vynzresearch.com/healthcare/global-breast-augmentation-market/request-sample
The demand for cosmetic surgery and aesthetic implants is growing at a substantial pace as a result of the importance given to physical appearance. Cosmetic procedures are seeing a massive increase around the world. breast augmentation is the most common aesthetic surgery.
In terms of geographies, APAC is one of the fastest-growing markets, mainly due to the quick adoption of cosmetic surgeries and growth in the number of surgeries especially in countries like China and India. Also, due to a high number of surgeries performed in Brazil, Latin America is estimated to serve as a lucrative segment.
Globally, 1,862,506 breast augmentation procedures were performed in 2018, compared to 1,677,319 procedures in 2017, according to the International Society of Cosmetic Plastic Surgery.
According to the American Cancer Society, women were diagnosed with 252,710 new cases of invasive breast cancer in 2017. In addition, women were diagnosed with 63,410 cases of in situ breast carcinoma.
Round breast implants are the most common type of implant and have increased in popularity over time due to their ability to increase the volume of the breasts and make them look fuller. They come in a variety of sizes and have a smooth or textured surface.
Some of the major key players in the breast augmentation market are Johnson & Johnson (U.S.A), Allergan (Ireland), Sientra (U.S.A), CEREPLAS (France), Laboratories Arion (France), Mentor Worldwide (U.S.A), GC Aesthetics (Ireland), and more…
Source: VynZ Research
No comments:
Post a Comment